Einrichtungen, die zum Universitätsklinikum Erlangen gehören

Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX). (2026) Burchert A, Nicolini FE, le Coutre P, Saussele S, Hochhaus A, Tuere E, Metzelder SK, et al. Journal article Potential of EEG and EEG/MEG skull conductivity estimation to improve source analysis in presurgical evaluation of epilepsy (2026) Vorwerk J, Rampp S, Wolters CH, Baumgarten D Journal article Validation of PARACELSUS score performance for the diagnosis of pyoderma gangrenosum: An international multicenter study with 1403 cases (2026) Moelleken M, Ortega-Loayza AG, Busch D, Erfurt-Berge C, Shinohara MM, Do A, Libertad Ortega Nuñez D, et al. Journal article Water sorption of dental resin composites: Is a new method the future? (2026) Heckel L, Belli R, Schüssler T, Fischer C, Lohbauer U Journal article Structured reporting of dental panoramic images in a hospital-based radiology setting: a comparative study (2026) Schnitzer ML, Biechele G, Schober E, Herr FL, Dascalescu C, Heimer M, Ebner R, et al. Journal article Natural medicines for radioprotection and radiosensitization: a bibliometric analysis of mechanisms and trends (2001–2025) (2026) Di Y, Song J, Wang Y, Meng L, Li J Journal article, Review article Calculation of silent substitution stimuli for full-field electroretinography using the SilentSubstiTutor application (2026) Huchzermeyer C, Kremers J Journal article Finger joint arthrodesis with the cup and cone technique: A simple and safe procedure Fingergelenkarthrodesen mittels Cup-and-Cone-Technik: Ein einfaches und sicheres Verfahren (2026) Sebald ATE, Arkudas A, Horch RE Journal article Erratum: Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial. (2026) Fietkau R, Ghadimi M, Grützmann R, Wittel UA, Jacobasch L, Uhl W, Croner RS, et al. Journal article, Erratum Real-world progression-free survival and overall survival in patients with HR+/HER2− advanced breast cancer treated in first-line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study (2026) Fasching P, Brucker C, Decker T, Engel A, Göhler T, Jackisch C, Janssen J, et al. Journal article